T cell responses in respiratory viral infections and chronic obstructive pulmonary disease

Every year, respiratory viruses like the common cold, flu, and respiratory syncytial virus (RSV) cause 200 million cases of viral pneumonia worldwide. For the 300 million people living with chronic obstructive pulmonary disease (COPD)—a progressive lung condition marked by emphysema and chronic bronchitis—these viruses are more than just a seasonal hassle: they’re a leading cause of life-threatening flare-ups (called acute exacerbations, or AECOPD). New research from Shouxiong Huang at the University of Cincinnati College of Medicine and Linfu Zhou at Nanjing Medical University’s First Affiliated Hospital reveals how T cells—the immune system’s key defenders—balance protection against viruses and damage to fragile lung tissue. Their findings, published in Chinese Medical Journal, offer critical insights into treating both respiratory infections and COPD.

How Respiratory Viruses Worsen COPD

COPD is driven by a mix of genetics, smoking, air pollution, and repeated infections. Viruses are particularly dangerous: studies show they trigger half of all AECOPD cases, with up to 64% of patients testing positive for viral genetic material during a flare-up. The most common culprit? Human rhinovirus (HRV), the virus behind most colds, which is found in 12–63% of AECOPD cases. Even stable COPD patients aren’t safe: 12–19% have ongoing viral infections, often from RSV or coronaviruses.

Viruses worsen COPD by damaging the airway lining, triggering inflammation, and disrupting the immune system. When a virus like HRV infects bronchial cells, it triggers the release of chemicals (cytokines and chemokines) that attract immune cells—including T cells—to the lungs. While this response helps clear the virus, it also damages healthy tissue, leading to more mucus, slower breathing, and permanent lung scarring.

The Role of T Cells: Protection vs. Damage

T cells are white blood cells that target specific invaders, like viruses. They’re activated in three ways:

Antigen presentation: Viral proteins (peptides) displayed on infected cells bind to T cell receptors.
Co-stimulation: Molecules on immune cells (like CD80/CD86) “turn on” T cells.
Cytokines: Chemical signals from other immune cells (like interleukin-2) boost T cell activity.

But T cells are a double-edged sword. They clear viruses—but their overactivity can cause the inflammation and tissue damage that defines COPD.

CD8+ T Cells: The Viral Killers

CD8+ T cells are the immune system’s “snipers.” They target cells infected with viruses (like flu or RSV) by:

Degranulation: Releasing proteins (perforin and granzymes) that punch holes in infected cells.
Cytokines: Producing interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) to stop viral replication.
Apoptosis: Triggering cell death in infected cells via Fas/FasL or TRAIL pathways.

Kinetics and Memory

When you get a respiratory virus, CD8+ T cells activate within 5–10 days (faster if you’ve been infected before). After clearing the virus, most die off—but a small subset, called tissue-resident memory T cells (TRM), stays in the lungs. These long-lived cells are critical for fast defense against repeat infections: in mice, TRM cells clear flu viruses days faster than circulating T cells.

Protection (and Cross-Protection)

CD8+ T cells don’t just fight the same virus—they can protect against related viruses. For example, flu viruses mutate constantly (antigenic drift), but CD8+ T cells targeting conserved viral proteins (like nucleoprotein, NP) can fight multiple flu subtypes. This “cross-subtype protection” is why some people with prior flu exposure have milder symptoms when a new strain emerges.

CD8+ T Cells in COPD

In COPD patients, CD8+ T cells are overabundant in the lungs—and their numbers inversely correlate with lung function (measured by FEV1, the amount of air exhaled in 1 second). These cells are hyperactive: they produce more perforin and granzyme B (cytotoxic proteins) but less of the receptors needed to fight viruses. This “dysfunctional” activation damages healthy lung tissue while failing to clear infections—worsening COPD over time.

CD4+ T Cells: The Immune Regulators

CD4+ T cells are the “managers” of the immune system. They don’t kill viruses directly—instead, they:

Help CD8+ T cells: Stimulate antigen-presenting cells (like dendritic cells) to activate CD8+ T cells via CD40/CD40L interactions.
Regulate B cells: Differentiate into follicular helper T cells (Tfh) to help B cells make antibodies against viruses.
Control inflammation: Regulatory T cells (Treg) suppress overactive immune responses to prevent tissue damage.

Subsets and Function

CD4+ T cells split into specialized subsets based on cytokines and transcription factors:

Th1: Produce IFN-γ and TNF-α to boost antiviral defenses.
Th2: Make IL-4, IL-5, and IL-13—helpful for parasites but damaging in COPD (attracts eosinophils, worsens inflammation).
Th17: Secrete IL-17, which recruits neutrophils but can inhibit CD8+ T cell function.
Treg: Produce IL-10 and TGF-β to calm inflammation—critical for preventing “cytokine storms” in severe infections.

Memory and Antibody Production

Like CD8+ T cells, CD4+ T cells form memory cells. For flu, memory CD4+ T cells targeting surface proteins (like hemagglutinin, HA) help B cells make neutralizing antibodies—while those targeting conserved proteins (like NP) support long-term immunity.

CD4+ T Cells in COPD

COPD patients often have autoreactive CD4+ T cells—cells that attack the body’s own elastin (a protein that keeps lungs elastic). These Th1-phenotype cells correlate with emphysema severity: they secrete CXCL10 (a pro-inflammatory chemokine) and drive the destruction of lung tissue. Treg cells, which normally suppress autoimmunity, are impaired in COPD—their numbers are low, and they fail to produce anti-inflammatory cytokines like IL-10.

What This Means for Treatment

The study highlights T cells as both heroes and villains in respiratory health. For viral infections, targeting TRM cells (e.g., via intranasal vaccines that boost lung-resident memory) could enhance fast, local defense. For COPD, therapies that rebalance T cell activity—like restoring Treg function or blocking overactive CD8+ T cells—might slow disease progression.

Importantly, the research emphasizes antigen specificity: T cells that target viral peptides (not self-proteins like elastin) are protective. This suggests peptide-based vaccines—focused on conserved viral proteins—could prevent both infections and COPD exacerbations.

Conclusion

Respiratory viruses and COPD are linked by a fragile balance of immune protection and damage. T cells are at the center of this balance: they clear viruses but can destroy lung tissue if unregulated. By understanding how T cells respond to viruses and COPD, researchers are one step closer to treatments that boost immunity without harming the lungs—a critical need for the millions living with these conditions.

Shouxiong Huang et al. Chinese Medical Journal 2021;134:1522–1534. doi.org/10.1097/CM9.0000000000001388

Was this helpful?

0 / 0